EOC will initiate a Phase II study of EOC202 in combination with chemotherapy in metastatic breast cancer in the second half of 2021. Additionally, the immunotherapy combination research of efti has recently demonstrated improved clinical benefits in OS and good safety profile from Immutep's on-going TACTI-002 study, which is a Phase II combination trial with pembrolizumab at first and second- line in patients with NSCLC and at second- line in patients with HNSCC. This regimen has synergistic effect with anti-PD-1 because the activation of APC and subsequent T cell recruitment with efti may lead to amplification of anti-tumor responses. EOC is also preparing such a combination therapy study and expects to kick off in the first half of 2022. EOC and Chime started collaborating in 2018 with technical transfer project for EOC202 ahead of scale-up and process optimization for clinical batch manufacture.